首页> 中文期刊> 《海南医科大学学报(英文版)》 >Effects of fuming tablet combined with operation on serum β2-mg, HbA1c, no and antioxidant capacity in patients with diabetic cataract

Effects of fuming tablet combined with operation on serum β2-mg, HbA1c, no and antioxidant capacity in patients with diabetic cataract

         

摘要

Objective: To observe the effect of oral fuming tablets on the levels of serum β2-microglobulin (β2-MG), Glycosylated hemoglobin (HbA1c), Nitric oxide (NO), Malondialdehyde (MDA) and superoxide dismutase (SOD) in patients with diabetic cataract (DC) after phacoemulsification combined with vitrectomy. Methods: A total of 90 patients with DC were randomly divided into control group (n=45) and observation group (n=45) according to the lottery method. Both groups were treated with conventional therapy. On this basis, the control group underwent phacoemulsification combined with vitrectomy. The observation group was treated with Fuming tablets on the basis of the control group. The levels of β2-MG, HbA1c, NO, MDA and SOD in peripheral blood were measured in all subjects. Result: Before treatment, there were no significant difference in serum levels of β2-MG, HbA1c, NO, MDA and SOD between the two groups. The levels of β2-MG, HbA1c, NO and MDA in the two groups after treatment were significantly lower than those before treatment. And the levels of β2-MG, HbA1c, NO and MDA of the observation group was notably lower than those of the control group. After treatment, the levels of SOD in the two groups were notably higher than those before treatment. And the levels of SOD of the observation group was notably higher than those of the control group after treatment. Conclusion: After phacoemulsification combined with vitrectomy, supplemented with Fuming tablet treatment can effectively reduce serum levels of β2-MG and HbA1c to improve the degree of fundus lesions in DC patients;reduce serum MDA and NO levels, increase the concentration of SOD, DC patients to restore the antioxidant energy. Fuming tablets are effective adjuvant drugs for clinical cataract surgery.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号